Certara (NASDAQ:CERT) Trading Up 8.8% After Analyst Upgrade

Certara, Inc. (NASDAQ:CERT - Get Free Report) shares shot up 8.8% on Monday after KeyCorp raised their price target on the stock from $15.00 to $18.00. KeyCorp currently has an overweight rating on the stock. Certara traded as high as $14.15 and last traded at $14.05. 905,668 shares were traded during trading, a decline of 20% from the average session volume of 1,138,576 shares. The stock had previously closed at $12.91.

A number of other brokerages have also recently weighed in on CERT. Barclays decreased their price objective on Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Stephens reissued an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, TD Cowen began coverage on shares of Certara in a research report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.17.

Hedge Funds Weigh In On Certara

Institutional investors and hedge funds have recently modified their holdings of the stock. Kopion Asset Management LLC lifted its position in Certara by 46.0% in the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock worth $5,918,000 after buying an additional 175,005 shares during the last quarter. Principal Financial Group Inc. grew its stake in Certara by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock valued at $5,660,000 after purchasing an additional 15,739 shares during the last quarter. Vontobel Holding Ltd. bought a new position in Certara in the fourth quarter worth about $1,295,000. Barclays PLC boosted its holdings in shares of Certara by 198.3% in the 3rd quarter. Barclays PLC now owns 70,525 shares of the company's stock valued at $825,000 after buying an additional 46,880 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Certara in the 4th quarter worth approximately $148,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Performance

The stock has a market cap of $2.28 billion, a P/E ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm's 50 day moving average is $11.62 and its 200 day moving average is $11.46.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.